An observational study in Neoplasm, Esophagus and Neoplasm, Squamous Cell, sponsored by Fudan University. Completed. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Fudan University · Observational
Among 27 studies in Esophageal Neoplasms by Fudan University — 13 open to participants now, 16 under way, 3 of them phase 3. Esophageal Neoplasms · Fudan University.
Among the 27 studies in Esophageal Neoplasms by Fudan University, this one is the 7th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2010, is one of 10 observational ones, and was the 16th registered.
1,873 studies on the registry are indexed under Esophageal Neoplasms; 501 are open to participants now.
This study's enrollment of 187 is close to the median of 200 across 432 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →13 of the 27 studies in Esophageal Neoplasms by Fudan University are open now, in 1 country. Each count lists the studies.
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 40 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2010.
Median enrollment 128 across the 17 interventional studies, 200 across the 10 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
Fudan University is the lead sponsor of 1,315 studies on the registry; 643 are open to participants now.
4 of the studies in Esophageal Neoplasms by Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914687Fudan UniversityEfficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | 2026-11-01 |
| NCT07272382Fudan UniversityOmega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer | 2027-06-05 |
| NCT07165210Fudan UniversityIncidence of 106TBL Lymph Node Metastasis | 2027-07-21 |
| NCT07165184Fudan UniversityIncidence of 107 Lymph Node Metastasis | 2027-07-21 |
Among the 27 studies in Esophageal Neoplasms by Fudan University, from their registry updates:
Nothing recorded among them since 2026-09-25.
In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).
In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS), which will combine the proportion of residual primary tumor cells and pre-treatment pathological T stage (prepT stage). The investigators will also try to improve ypTNM stage by results of PTBS.
Patients with ESCC undergoing nCRT at the Department of Thoracic Surgery, Zhongshan Hospital of Fudan University (training cohort), and the Department of Thoracic Surgery, Zhongshan Hospital Xiamen Branch (validation cohort), between January 2010 and February 2019 were reviewed. The inclusion criteria were (I) thoracic ESCC; (II) McKeown or Ivor-Lewis transthoracic approach; (III) locally advanced resectable tumor with cT3-4aNany staging treated with nCRT; (IV) no history of concomitant or prior malignancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Training cohort will be used to find the best calculation and cut-off values for PTBS in ESCC after nCRT.
Procedure: nCRT
The study's conclusion will be verified in Zhongshan Hospital Xiamen branch.
Procedure: nCRT
ESCC patients that recieved surgery and nCRT.
Five-year survival of patients
The survival of the patients was recorded by follow-up for five years after surgery.
Time frame: From surgery to the end of follow-up(at least 5 years later)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2010 to primary completion in Dec 2021, 138 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.